Md Akheruzzaman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Md Akheruzzaman has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Nikhil V. Dhurandhar
Department of Nutritional Sciences, Texas Tech University, Lubbock, TX
6 shared publications - Vijay Hegde
Department of Nutritional Sciences, Texas Tech University, Lubbock, USA
5 shared publications - Andrew C. Shin
Neurobiology of Nutrition Laboratory, Department of Nutritional Sciences, College of Health & Human Sciences, Texas Tech University, Lubbock, TX, 79409
2 shared publications Vijay Hegde
Department of Nutritional Sciences, Texas Tech University, Lubbock, TX, 79409, USA
2 shared publications- Zahra Feizy
Department of Nutritional Sciences, Texas Tech University, Lubbock, TX 79414, USA
2 shared publications Abu Bakkar Siddik
Texas Tech Univ, Dept Nutr Sci, Lubbock, TX 79409 USA
1 shared publication
Latest Publications
- Open Access
Effect of unprocessed red meat on obesity and related factors: A systematic review and meta‐analysis
Objective: The objective of this study was to conduct a systematic review and meta‐analysis of intervention trials that have determined the effect of unprocessed red meat (URM) intake on obesity‐related outcomes. Methods: The populations, interventions, controls, and outcomes (PICO) framework was used to create questions to search seven databases from July 29, 2020, to August 21, 2020. Two reviewers independently screened 5630 references. English‐language intervention trials in adults testing the effect of URM on obesity‐related outcomes were included. Twenty‐four studies met selection criteria. A random‐effects model was developed to calculate pooled effect sizes. The DerSimonian‐Laird estimator was used to estimate the variance of the true effect sizes. An interactive dashboard was published to provide transparent analysis and data presentation. Results: We found no significant effect of URM for BMI, body weight, or percent body fat based on unfiltered pooled effect sizes. Filtered pooled effect size analysis showed a slight adverse effect of URM for total cholesterol and low‐density lipoprotein cholesterol. Conclusions: Studies did not show an effect of URM on weight gain, obesity, or related metabolic conditions. This may help clinicians when considering the use of URM for patients. Longer studies may be needed for observing obesity development in case the effect of URM on weight gain is small and needs a much longer time to express.
Open AccessEffect of unprocessed red meat on obesity and related factors: A systematic review and meta‐analysis
Objective: The objective of this study was to conduct a systematic review and meta‐analysis of intervention trials that have determined the effect of unprocessed red meat (URM) intake on obesity‐related outcomes. Methods: The populations, interventions, controls, and outcomes (PICO) framework was used to create questions to search seven databases from July 29, 2020, to August 21, 2020. Two reviewers independently screened 5630 references. English‐language intervention trials in adults testing the effect of URM on obesity‐related outcomes were included. Twenty‐four studies met selection criteria. A random‐effects model was developed to calculate pooled effect sizes. The DerSimonian‐Laird estimator was used to estimate the variance of the true effect sizes. An interactive dashboard was published to provide transparent analysis and data presentation. Results: We found no significant effect of URM for BMI, body weight, or percent body fat based on unfiltered pooled effect sizes. Filtered pooled effect size analysis showed a slight adverse effect of URM for total cholesterol and low‐density lipoprotein cholesterol. Conclusions: Studies did not show an effect of URM on weight gain, obesity, or related metabolic conditions. This may help clinicians when considering the use of URM for patients. Longer studies may be needed for observing obesity development in case the effect of URM on weight gain is small and needs a much longer time to express.
- 3 November 2023
- Published by Taylor & Francis
- p. 319-328
COVID-19, Other Microbial Infections, and Obesity
Obesity results from a complex interplay between biological and environmental factors. The term “obesities” may more aptly describe its multifactorial etiology. Obesity increases susceptibility to microbial infection and may lead to poor outcomes. For example, patients with obesity have a poor prognosis and greater mortality following influenza or COVID-19 infection. Conversely, several viruses, bacteria, parasites, and scrapie agents can contribute to obesity. Among the adipogenic microbes, human adenovirus-36 (Ad36) is extensively investigated for its correlative or causative links with obesity in humans and animal models. Natural or experimental exposure to Ad36 is also linked with lower serum lipids and better glycemic control. The E4orf1 gene of Ad36 is responsible for improving glycemic control and shows strong therapeutic potential. Identifying the contributions of various pathogens in obesity may lead to effective treatment of subtypes of obesity through the development of respective vaccines or other treatments. Finally, for individuals suffering from the stigma of obesity, the possibility that a microbe can cause some types of obesity provides strong assurance that obesity is not a choice or a moral failure, but a serious disease.
- 3 November 2023
- Published by Taylor & Francis
- p. 319-328
COVID-19, Other Microbial Infections, and Obesity
Obesity results from a complex interplay between biological and environmental factors. The term “obesities” may more aptly describe its multifactorial etiology. Obesity increases susceptibility to microbial infection and may lead to poor outcomes. For example, patients with obesity have a poor prognosis and greater mortality following influenza or COVID-19 infection. Conversely, several viruses, bacteria, parasites, and scrapie agents can contribute to obesity. Among the adipogenic microbes, human adenovirus-36 (Ad36) is extensively investigated for its correlative or causative links with obesity in humans and animal models. Natural or experimental exposure to Ad36 is also linked with lower serum lipids and better glycemic control. The E4orf1 gene of Ad36 is responsible for improving glycemic control and shows strong therapeutic potential. Identifying the contributions of various pathogens in obesity may lead to effective treatment of subtypes of obesity through the development of respective vaccines or other treatments. Finally, for individuals suffering from the stigma of obesity, the possibility that a microbe can cause some types of obesity provides strong assurance that obesity is not a choice or a moral failure, but a serious disease.
- 12 January 2022
- Published by Springer Nature in International Journal of Obesity
- Vol. 46 (5) , 918-925
E4orf1-induced reduction in endogenous insulin level is independent of pancreas endocrine function
Background Obesity is often associated with hyperinsulinemia due to insulin resistance. In mice models of hyperinsulinemia, adenovirus-derived E4orf1 protein promotes glucose disposal via insulin-independent pathway, and reduces insulin response to glucose load, described as its “Insulin Sparing Action”. This is likely because less insulin is needed for disposing glucose in presence of E4orf1, however, there are other potential possibilities. This study determined if E4orf1 reduces insulin response to glucose load because it a) suppresses the ability of pancreatic β-cells to secret insulin, or b) upregulates glucagon production by the pancreas. Methods C57BL/6J wild type (control) and transgenic C57BL/6J (E4orf1) mice that express E4orf1 protein in adipose tissue upon doxycycline feeding, were used. Post-doxycycline feeding, insulin and glucagon secretion in response to glibenclamide or phenylephrine were compared between the two groups. The pancreases were examined for histological changes. Results In response to glibenclamide, E4orf1 mice secreted more insulin and exhibited lower blood glucose compared to control (47.4 ± 4.4 vs 27.4 ± 3.7 mg/dl, p < 0.003), but showed no difference in glucagon secretion. Post-phenylephrine injection, no differences were observed between the two groups for glucagon or insulin, except E4orf1 mice had a lower blood glucose rise after 10-min of injection compared to the control (39.7 ± 4.7 vs. 58.3 ± 7.5 mg/dl, p < 0.05). E4orf1 mice had significantly larger pancreatic islets and higher number of islets per mm2 tissue area. Neither the size nor the number of islets met the criteria of hypertrophy or hyperplasia. Conclusions/interpretation E4orf1 retains and may enhance the ability of the pancreases to secret insulin in response to insulin secretagogue. Glucagon does not seem to play a role in the Insulin Sparing Action of E4orf1. Overall, the histology studies support better pancreatic islet health in presence of E4orf1, compared to that in control mice. The “insulin-independent” role of E4orf1 has potential therapeutic implications in addressing hyperinsulinemia in obesity.
- 12 January 2022
- Published by Springer Nature in International Journal of Obesity
- Vol. 46 (5) , 918-925
E4orf1-induced reduction in endogenous insulin level is independent of pancreas endocrine function
Background Obesity is often associated with hyperinsulinemia due to insulin resistance. In mice models of hyperinsulinemia, adenovirus-derived E4orf1 protein promotes glucose disposal via insulin-independent pathway, and reduces insulin response to glucose load, described as its “Insulin Sparing Action”. This is likely because less insulin is needed for disposing glucose in presence of E4orf1, however, there are other potential possibilities. This study determined if E4orf1 reduces insulin response to glucose load because it a) suppresses the ability of pancreatic β-cells to secret insulin, or b) upregulates glucagon production by the pancreas. Methods C57BL/6J wild type (control) and transgenic C57BL/6J (E4orf1) mice that express E4orf1 protein in adipose tissue upon doxycycline feeding, were used. Post-doxycycline feeding, insulin and glucagon secretion in response to glibenclamide or phenylephrine were compared between the two groups. The pancreases were examined for histological changes. Results In response to glibenclamide, E4orf1 mice secreted more insulin and exhibited lower blood glucose compared to control (47.4 ± 4.4 vs 27.4 ± 3.7 mg/dl, p < 0.003), but showed no difference in glucagon secretion. Post-phenylephrine injection, no differences were observed between the two groups for glucagon or insulin, except E4orf1 mice had a lower blood glucose rise after 10-min of injection compared to the control (39.7 ± 4.7 vs. 58.3 ± 7.5 mg/dl, p < 0.05). E4orf1 mice had significantly larger pancreatic islets and higher number of islets per mm2 tissue area. Neither the size nor the number of islets met the criteria of hypertrophy or hyperplasia. Conclusions/interpretation E4orf1 retains and may enhance the ability of the pancreases to secret insulin in response to insulin secretagogue. Glucagon does not seem to play a role in the Insulin Sparing Action of E4orf1. Overall, the histology studies support better pancreatic islet health in presence of E4orf1, compared to that in control mice. The “insulin-independent” role of E4orf1 has potential therapeutic implications in addressing hyperinsulinemia in obesity.
- Open Access
- 3 May 2021
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 9 (1) , e002096
Antidiabetic E4orf1 protein prevents hepatic steatosis and reduces markers of aging-related cellular damage in high fat fed older mice
Introduction: Older age is associated with greater prevalence of hyperinsulinemia, type 2 diabetes, and fatty liver disease. These metabolic conditions and aging are bidirectionally linked to mitochondrial dysfunction and telomere attrition. Although effectively addressing these conditions is important for influencing the health and the lifespan, it is particularly challenging in older age. We reported that E4orf1, a protein derived from human adenovirus Ad36, reduces hyperinsulinemia, improves glucose clearance, and protects against hepatic steatosis in younger mice exposed to high fat diet (HFD). Here, we tested if E4orf1 will improve glycemic control, liver fat accumulation, mitochondrial integrity, and reduce telomere attrition in older mice. Research design and methods: We used 9-month-old mice that inducibly expressed E4orf1 in adipose tissue and non-E4orf1 expressing control mice. Mice were maintained on a 60% (kcal) HFD for 20 weeks and glycemic control was determined by intraperitoneal glucose tolerance test at week 20. Following 20 weeks of HF-feeding, mice were sacrificed and liver tissues collected to determine the expression of aging genes using qRT-PCR based RT2 Profiler PCR array. Results: Compared with the control mice, E4orf1 significantly improved glycemic control and reduced hepatic steatosis and fibrosis. Additionally, E4orf1 maintained markers of mitochondrial integrity and telomere attrition. Conclusion: E4orf1 has the potential to improve glycemic control in older mice, and the improvement persists even after longer term exposure. E4orf1 expression also maintains mitochondrial integrity and telomere attrition, thus delaying age-associated diseases. This provides strong evidence for therapeutic utility of E4orf1 in improving age-associated metabolic and cellular changes that occur with aging in humans.
- 3 May 2021
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 9 (1) , e002096
Open AccessAntidiabetic E4orf1 protein prevents hepatic steatosis and reduces markers of aging-related cellular damage in high fat fed older mice
Introduction: Older age is associated with greater prevalence of hyperinsulinemia, type 2 diabetes, and fatty liver disease. These metabolic conditions and aging are bidirectionally linked to mitochondrial dysfunction and telomere attrition. Although effectively addressing these conditions is important for influencing the health and the lifespan, it is particularly challenging in older age. We reported that E4orf1, a protein derived from human adenovirus Ad36, reduces hyperinsulinemia, improves glucose clearance, and protects against hepatic steatosis in younger mice exposed to high fat diet (HFD). Here, we tested if E4orf1 will improve glycemic control, liver fat accumulation, mitochondrial integrity, and reduce telomere attrition in older mice. Research design and methods: We used 9-month-old mice that inducibly expressed E4orf1 in adipose tissue and non-E4orf1 expressing control mice. Mice were maintained on a 60% (kcal) HFD for 20 weeks and glycemic control was determined by intraperitoneal glucose tolerance test at week 20. Following 20 weeks of HF-feeding, mice were sacrificed and liver tissues collected to determine the expression of aging genes using qRT-PCR based RT2 Profiler PCR array. Results: Compared with the control mice, E4orf1 significantly improved glycemic control and reduced hepatic steatosis and fibrosis. Additionally, E4orf1 maintained markers of mitochondrial integrity and telomere attrition. Conclusion: E4orf1 has the potential to improve glycemic control in older mice, and the improvement persists even after longer term exposure. E4orf1 expression also maintains mitochondrial integrity and telomere attrition, thus delaying age-associated diseases. This provides strong evidence for therapeutic utility of E4orf1 in improving age-associated metabolic and cellular changes that occur with aging in humans.
- Open Access
- 12 August 2020
- Published by Springer Nature in Nutrition & Diabetes
- Vol. 10 (1) , 1-3
Potentially modifiable factors to reduce severity of COVID-19 in type 2 diabetes
- 12 August 2020
- Published by Springer Nature in Nutrition & Diabetes
- Vol. 10 (1) , 1-3
Open AccessPotentially modifiable factors to reduce severity of COVID-19 in type 2 diabetes
- Open Access
- 14 April 2020
- Published by Springer Nature in Nutrition & Diabetes
- Vol. 10 (1) , 1-12
Reducing endogenous insulin is linked with protection against hepatic steatosis in mice
Background: Obesity and type 2 diabetes (T2D) are closely associated with hepatic steatosis (HS), which if untreated can advance to serious liver conditions. Since insulin promotes hepatic lipogenesis, reducing hyperinsulinemia may help in treating HS. E4orf1 is an adenovirus-derived protein that improves glucose clearance independent of insulin, lowers insulin amount required for glucose disposal, and reduces HS. As a next step, we evaluated the mechanism for E4orf1-induced reduction in HS and tested that E4orf1 does not induce hypoglycemia, an important attribute for its application as a potential anti-diabetic agent.Methods: C57Bl/6J mice that transgenically express E4orf1 in adipose tissue (E4orf-Tg) and wild-type (WT) mice received a chow diet for 6 weeks, followed by a high-fat (HF) diet for additional 10 weeks. Body composition, blood glucose, and serum insulin levels upon glucose load were measured at 0, 6, 7, and 16 weeks. Serum free fatty acid (FFA), triglyceride (TG), and hepatic TG were measured at study termination. We compared histology and the mRNA/protein markers of hepatic and adipose tissue lipid metabolism between the two groups of mice.Results: On chow diet, both groups remained normoglycemic, but E4orf1 expression reduced insulin response. On HF diet, glycemic control in WT deteriorated, whereas E4orf1 significantly enhanced glycemic control, lowered insulin response, reduced hepatic triglycerides, and serum FFA. Overall, a comparison of hepatic mRNA and/or protein expression suggested that E4orf1 expression significantly decreased de novo lipogenesis (DNL) and intracellular lipid transport and increased fat oxidation and TG export. Adipose tissue mRNA and protein markers suggested that E4orf1 expression lowered DNL and increased lipolysis.Conclusion: Considering that E4orf1 is not secreted in circulation, we postulate that reduced endogenous insulin in E4orf1 mice indirectly contributes to reduce HS by altering hepatic lipid metabolism, including lipogenesis. This study underscores the possibility of indirectly impacting HS by manipulating adipose tissue metabolism.
- 14 April 2020
- Published by Springer Nature in Nutrition & Diabetes
- Vol. 10 (1) , 1-12
Open AccessReducing endogenous insulin is linked with protection against hepatic steatosis in mice
Background: Obesity and type 2 diabetes (T2D) are closely associated with hepatic steatosis (HS), which if untreated can advance to serious liver conditions. Since insulin promotes hepatic lipogenesis, reducing hyperinsulinemia may help in treating HS. E4orf1 is an adenovirus-derived protein that improves glucose clearance independent of insulin, lowers insulin amount required for glucose disposal, and reduces HS. As a next step, we evaluated the mechanism for E4orf1-induced reduction in HS and tested that E4orf1 does not induce hypoglycemia, an important attribute for its application as a potential anti-diabetic agent.Methods: C57Bl/6J mice that transgenically express E4orf1 in adipose tissue (E4orf-Tg) and wild-type (WT) mice received a chow diet for 6 weeks, followed by a high-fat (HF) diet for additional 10 weeks. Body composition, blood glucose, and serum insulin levels upon glucose load were measured at 0, 6, 7, and 16 weeks. Serum free fatty acid (FFA), triglyceride (TG), and hepatic TG were measured at study termination. We compared histology and the mRNA/protein markers of hepatic and adipose tissue lipid metabolism between the two groups of mice.Results: On chow diet, both groups remained normoglycemic, but E4orf1 expression reduced insulin response. On HF diet, glycemic control in WT deteriorated, whereas E4orf1 significantly enhanced glycemic control, lowered insulin response, reduced hepatic triglycerides, and serum FFA. Overall, a comparison of hepatic mRNA and/or protein expression suggested that E4orf1 expression significantly decreased de novo lipogenesis (DNL) and intracellular lipid transport and increased fat oxidation and TG export. Adipose tissue mRNA and protein markers suggested that E4orf1 expression lowered DNL and increased lipolysis.Conclusion: Considering that E4orf1 is not secreted in circulation, we postulate that reduced endogenous insulin in E4orf1 mice indirectly contributes to reduce HS by altering hepatic lipid metabolism, including lipogenesis. This study underscores the possibility of indirectly impacting HS by manipulating adipose tissue metabolism.
- 18 December 2018
- Published by Wiley in Obesity Reviews
- Vol. 20 (4) , 499-509
Twenty‐five years of research about adipogenic adenoviruses: A systematic review
Summary: Infectious etiology is implicated in chronic diseases such as gastric ulcer or atherosclerosis. However, “infection” is a recent term in the field of obesity. Since the first report in 1982 of obesity due to infection, several microbes have been linked to obesity. Among the adipogenic microbes, avian adenovirus SMAM‐1 and human adenovirus Ad36 have been studied most extensively for the past 25 years. Here, we present a systematic review of literature about SMAM‐1 and Ad36. Reports from North America, Europe, and Asia reveal strong evidence that Ad36 causes obesity in animals and paradoxically improves glycemic control, and in vitro data provides mechanistic explanation. Considering that experimental Ad36 infection of humans is unlikely, its causative role in human obesity or glycemic control has not been demonstrated unequivocally. Nonetheless, most, but not all, observational studies in children and adults link Ad36 infection to obesity and improvement in glycemic control. The E4orf1 gene of Ad36 was identified as responsible for better glycemic control. Overall, 25 years have considerably advanced knowledge about the role of infection in obesity. Potential translational benefits include the development of vaccines to prevent Ad36‐induced obesity and drug development based on the E4orf1 protein to improve glycemic control.
- 18 December 2018
- Published by Wiley in Obesity Reviews
- Vol. 20 (4) , 499-509
Twenty‐five years of research about adipogenic adenoviruses: A systematic review
Summary: Infectious etiology is implicated in chronic diseases such as gastric ulcer or atherosclerosis. However, “infection” is a recent term in the field of obesity. Since the first report in 1982 of obesity due to infection, several microbes have been linked to obesity. Among the adipogenic microbes, avian adenovirus SMAM‐1 and human adenovirus Ad36 have been studied most extensively for the past 25 years. Here, we present a systematic review of literature about SMAM‐1 and Ad36. Reports from North America, Europe, and Asia reveal strong evidence that Ad36 causes obesity in animals and paradoxically improves glycemic control, and in vitro data provides mechanistic explanation. Considering that experimental Ad36 infection of humans is unlikely, its causative role in human obesity or glycemic control has not been demonstrated unequivocally. Nonetheless, most, but not all, observational studies in children and adults link Ad36 infection to obesity and improvement in glycemic control. The E4orf1 gene of Ad36 was identified as responsible for better glycemic control. Overall, 25 years have considerably advanced knowledge about the role of infection in obesity. Potential translational benefits include the development of vaccines to prevent Ad36‐induced obesity and drug development based on the E4orf1 protein to improve glycemic control.